Scientific Knowledge Exchange on melanoma
In this Scientific Knowledge Exchange Prof. Dr. Reinhard Dummer, University Hospital of Zurich, and Prof. Dr. Christoph Höller, Medical University of Vienna, discuss about Immunotherapy for Melanoma.
Video Contents
00:27 No Practice Changing Studies, but … 02:20 Neoadjuvant concepts (T-vec-Study) 04:52 BRAF/MEK Combinations 06:23 Immunotherapy vs Targeted Therapy 09:35 Negative result of ido1-inhibitor epacadostad combined with pembrolizumab 14:04 Promising early Study Result 16:55 The disadvantage of different reporting systemsSource: ASCO 2018
The following abstracts are discussed in this SKE:
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.
https://meetinglibrary.asco.org/record/159079/abstract
4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.
https://meetinglibrary.asco.org/record/159075/abstract
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.
https://meetinglibrary.asco.org/record/159079/abstract
Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.